CED News

Paradigm Genetics, Inc. (Nasdaq: PDGM) and StemCo BioMedical, Inc. recently announced a research collaboration for the biochemical profiling of adult human stem cells. Under the terms of the agreement, Paradigm will use its proprietary metabolomics technology platform, MetaVantage^TM, to elucidate the biochemical profiles of adult stem cells supplied by StemCo, and will use the generated biochemical profiles to identify all of the small molecules present in the cells. Paradigm will retain all intellectual property rights to any discoveries related to the biochemical profiles and the compounds themselves, which Paradigm believes will have significant value for drug discovery and development. StemCo will retain rights related to the studied stem cells themselves for diagnostic or therapeutic purposes. Financial details were not disclosed. www.paragen.com